PT
ThePornDude
OnlyFans Finder
#1 AI Nude Generator
Sex 'n Dolls
AI Girlfriend
Notícias e Atualizações de Maat
Voltar ao PerfilReceba as últimas notícias, atualizações e conteúdo sobre Maat. Não perca nenhuma fofoca ou novo conteúdo adulto dela.
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for...
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Regulatory MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company a...
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory We are grateful for the confidence shown in MaaT Pharma a...
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030...
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing if cash crunch clears
A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its prima...
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026
In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorizati...
Maat Pharma SA MAAT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...
MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology
MaaT Pharma is charting new territory in oncology by positioning microbiome-driven therapy as a pote...
MaaT microbiota drug shows survival advantage in GvHD
MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with ne...
AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology
Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for Ma...
A simple memory technique helped chemotherapy patients stay mentally sharp during treatment
Chemotherapy patients who learned structured memory and attention strategies through a workbook-base...
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
In June 2025, the European Medicines Agency accepted for review the marketing authorization submissi...
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
LYON, France--(BUSINESS WIRE)--Regulatory These encouraging findings from the IASO Phase 1b trial c...
Maat (Atenolol) Drug Price and Information
atenolol (Maat) (Maat) blocks beta-1 receptors, which are present on the heart. This prevents the ac...
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
LYON, France--(BUSINESS WIRE)--$MAAT--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”)...
Lisbon’s MAAT Museum Heralds New Era for Contemporary Art in Portugal
As a sparkling new building is unveiled for the Museum of Art, Architecture and Technology in Lisbon...
Zindagi Gulzar Hai to end: What the replacement show ‘Maat’ is all about
Zindagi, the new entertainment channel is bringing to its viewers a show which was amongst the most ...
MaaT Pharma to Hold Annual General Meeting on June 16, 2026
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a lea...
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
LYON, France--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”), a cli...
Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA
MaaT Pharma’s 18-month struggle to get out from under an FDA clinical hold may be entering its end...
MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD
A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the mi...
MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a lea...
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
LYON, France--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”), a cli...
Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)
LYON, France--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”), a cli...